Tag Archives: IMV

IMV (IMV) Receives a Hold from B.Riley FBR

In a report released today, Mayank Mamtani from B.Riley FBR maintained a Hold rating on IMV (IMV – Research Report), with a price target of $3.00. The company’s shares closed last Monday at $2.89. According to TipRanks.com, Mamtani is a

IMV (IMV) Receives a Rating Update from a Top Analyst

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on IMV (IMV – Research Report), with a price target of $13.00. The company’s shares closed last Friday at $2.95. According to TipRanks.com, Pantginis is a

Echelon Wealth Partners Remains a Buy on IMV (IMV)

In a report issued on May 21, Douglas Loe from Echelon Wealth Partners maintained a Buy rating on IMV (IMV – Research Report), with a price target of C$9.00. The company’s shares closed last Friday at $3.53. According to TipRanks.com,

B.Riley FBR Reaffirms Their Hold Rating on IMV (IMV)

B.Riley FBR analyst Mayank Mamtani maintained a Hold rating on IMV (IMV – Research Report) today and set a price target of $3.00. The company’s shares closed last Monday at $2.80. According to TipRanks.com, Mamtani is a 5-star analyst with

Analysts Offer Insights on Healthcare Companies: IMV (NASDAQ: IMV), Ovid Therapeutics (NASDAQ: OVID) and ImmunoGen (NASDAQ: IMGN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IMV (IMV – Research Report), Ovid Therapeutics (OVID – Research Report) and ImmunoGen (IMGN – Research Report) with bullish sentiments. IMV (IMV)

Why Did B.Riley FBR Downgrade IMV’s Stock?

IMV (IMV – Research Report) received a Hold rating and a $3.00 price target from B.Riley FBR analyst Mayank Mamtani today. The company’s shares closed last Tuesday at $1.60, close to its 52-week low of $1.36. According to TipRanks.com, Mamtani